Federal contract award
75A50121C00059
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 334519 — Other Measuring and Controlling Device Manufacturing |
| PSC | AN42 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $139.0M |
| Current contract value | $139.0M |
| Potential contract value / ceiling | $156.7M |
| Start date | Aug 2, 2021 |
| Current end date | Nov 30, 2029 |
| Potential end date | Nov 30, 2031 |
| Latest award activity | Sep 1, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 21 of 21 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 1, 2026 | P00021 | $3.4M | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING FOR CLINS 0005, 0006, 0008, UPDATE ARTICLES B.2.2. OPTION COSTS, B.3. ADVANCED UNDERSTANDINGS, AND SECTION J - LIST OF ATTACHMENTS, ATTACHMENT 1 - STATEMENT OF WORK DATED AUGUST 1, 2 |
| Aug 21, 2026 | P00020 | $0 | THE PURPOSE OF THIS ADMINISTRATIVE MODIFICATION IS TO CORRECT THE PERIOD OF PERFORMANCE FOR CLINS 0001, 0004, 0005, 0006, 0007, 0008, AND 0009 TO ALIGN WITH IPP. |
| May 29, 2026 | P00019 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE B.3 ADVANCED UNDERSTANDING, ITEM 6. SUBCONTRACTS AND CONSULTANTS, AND THE STATEMENT OF WORK DATED APRIL 16, 2026; AT NO ADDITIONAL COST TO THE GOVERNMENT. |
| Apr 7, 2026 | P00018 | $0 | FAR PART 43.103 - UNIATERAL MODIFICATION |
| Feb 27, 2026 | P00017 | $35.0M | FAR PART 43.103(A) - BILATERAL MODIFICATION |
| Feb 20, 2026 | P00016 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO CORRECT THE PERIOD OF PERFORMANCE FOR CLIN0008/OPTION 7 AND CLIN0004/OPTION 5 TO ALIGN WITH IPP. |
| Dec 15, 2025 | P00015 | $0 | THE PURPOSE OF THIS NO-COST EXTENSION MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE THROUGH FEBRUARY 28, 2026, FOR CLIN 0008/OPTION 7 FOR THE COMPLETION OF A SUCCESSFUL PHASE 1 CLINICAL STUDY CONTINUED SCALE UP, SUSTAINING, AND VERIFICATION TES |
| Aug 4, 2025 | P00014 | $3.3M | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING FOR CLINS 0001, 0005, 0008, 0009, EXTEND THE PERIOD OF PERFORMANCE THROUGH JUNE 30, 2026, FOR CLINS 0004 AND 0005; AND CLIN 0009 THROUGH FEBRUARY 28, 2026, DUE TO DELAY IN COMPLETION |
| Apr 30, 2025 | P00013 | $0 | THE PURPOSE OF THIS NO-COST EXTENSION MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE (POP) OF CLIN 0001 (BASE) AND CLIN 0004 (OPTION 3) TO 12/31/2025, UPDATE ARTICLES B.2.1 BASE PERIOD (CLIN 0001), B.2.2 OPTION COSTS (CLINS 0002-0009), B.3 ADVAN |
| Dec 20, 2024 | P00012 | $0 | THE PURPOSE OF THIS NO-COST EXTENSION MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE (POP) OF CLIN 0002 (OPTION 1) TO 2/28/2025 DUE TO THE DELAY IN COMPLETING THE DRYER/SEALER SCALE-UP AND MANUFACTURING, AND CLIN 0003 (OPTION 2) TO 3/31/2025 DUE |
| Aug 22, 2024 | P00011 | $0 | THE PURPOSE OF THIS NO-COST EXTENSION MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE (POP) OF CLIN 0001 (BASE) TO 6/30/2025, CLIN 0002 (OPTION 1) TO 12/31/2024, AND CLIN 0003 (OPTION 2) TO 12/31/2024. |
| Aug 9, 2024 | P00010 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO CORRECT THE PERIOD OF PERFORMANCE TO ALIGN IPP FOR CLIN0005 (OPTION 4). |
| Apr 12, 2024 | P00009 | $13.9M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FUND OPTION 8/CLIN0009, PROVIDE SUPPLEMENTAL FUNDING FOR CLINS 0001, 0002, 0003, 0004, 0005, UPDATE SOW DATED 12/26/23, AND EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0001 THROUGH DECEMBER 29, 2024, C |
| Mar 25, 2024 | P00008 | $0 | THE PURPOSE OF THIS NO-COST EXTENSION MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE (POP) OF CLIN 0002 (OPTION 1) TO 4/30/2024. |
| Dec 15, 2023 | P00007 | $0 | THE PURPOSE OF THIS NO-COST EXTENSION MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE (POP) OF CLIN 0002 (OPTION 1) TO 3/30/2024, CLIN 0003 (OPTION 2) TO 6/30/2024, AND CLIN 0004 (OPTION 3) TO 9/30/2024. |
| Sep 5, 2023 | P00006 | $2.8M | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW. |
| May 23, 2023 | P00005 | $41.3M | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW. |
| Mar 17, 2023 | P00004 | $2.9M | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW. |
| Dec 13, 2022 | P00003 | $4.8M | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW. |
| Jun 10, 2022 | P00002 | $11.8M | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW. |
| Aug 2, 2021 | 0 | $19.9M | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW. |
Estimated positioning window
Nov 30, 2030 – May 30, 2031
Recompete signal: . Rule-based research score; positioning dates are estimates.
35/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 35/100. Available recorded signals: 30 points.
- Contract end 2031-11-30 (1855 days from calculation)
- +5 points
- 1 historical awards in this buyer and category group
- +0 points
- 21 recorded award transactions
- +10 points
- Latest award action: 2026-09-01
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.